Genome Profiling is an immune system focused functional epigenomics company that is creating a new category of molecular diagnostic and drug responder stratification blood tests to solve unmet needs in oncology and non-oncology diseases that other techniques cannot easily or economically address. GenPro’s cloud-based EpiMarker Platform combines novel, proprietary science, and machine learning to rapidly elucidate the immune system’s circulating white blood cells’ genome-wide epigenetic (DNA methylation) response to disease intrusion and drug-induced change into definitive epigenetic biomarkers, called “EpiMarkers”. EpiMarkers are translated into easy to perform, non-intrusive blood tests. A precision EpiMarker blood test to definitively diagnose Endometriosis is in development as the first in a planned pipeline of five novel immune system EpiMarker blood tests. Endometriosis is a painful, progressive pelvic disease affecting ~15% of women between 13-to-40 years of age for which expensive and invasive laparoscopic surgeries are the standard of care for disease diagnosis with 50% to 80% accuracy depending on the surgeon’s experience and expertise, and typically requiring multiple surgical episodes over several years. An EpiMarker precision blood test would change clinical practice, significantly improve patient care, and profoundly reduce the cost of endometriosis care. GenPro’s business model is driven by cooperative development and licensing partnerships with biopharma, molecular diagnostic, and genomic testing companies wherein GenPro discovers and develops immuno-EpiMarkers into commercializable tests within ~ 18 months for licensing to the partner for commercialization. Cooperative development and licensing partnerships are tailored to each partner’s goals.